Integration of toxicological approaches with "omic" and related technologies to elucidate mechanisms of carcinogenic action: Propiconazole, an example

Cancer Letters

Volumn 334, Issue 1, 2013, Pages 20-27

  Nesnow, Stephen ^a  

^a NONE   (United States)

Author keywords

CYP; Genomics; Hepatocarcinogenesis; Mechanisms; Metabolomics; Propiconazole; Proteomics; ROS

Indexed keywords

CELL NUCLEUS RECEPTOR; CHOLESTEROL; CYTOCHROME P450; MEVALONIC ACID; PROPICONAZOLE; REACTIVE OXYGEN METABOLITE; RETINOIC ACID; CARCINOGEN; DNA ADDUCT; TRIAZOLE DERIVATIVE;

ADVERSE OUTCOME; CARCINOGENICITY; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CLINICAL EFFECTIVENESS; CYTOCHROME P450 GENE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA ADDUCT; DRUG EFFICACY; DRUG SAFETY; FEEDBACK SYSTEM; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENOME ANALYSIS; GENOMICS; HUMAN; LIVER CARCINOGENESIS; LIVER LEVEL; METABOLOMICS; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; SHORT SURVEY; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; EXPERIMENTAL LIVER NEOPLASM; LIVER; METABOLISM; METABOLOME; MOUSE; MUTATION; PROCEDURES; TOXICOLOGY;

MUS;

ANIMALS; CARCINOGENS; CELL PROLIFERATION; CHOLESTEROL; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; FEEDBACK, PHYSIOLOGICAL; GENOMICS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; METABOLOME; MICE; MUTATION; OXIDATIVE STRESS; PROTEOMICS; REACTIVE OXYGEN SPECIES; TOXICOLOGY; TRETINOIN; TRIAZOLES;

EID: 84887935106     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.003     Document Type: Review

References (81)

1. Burgess-Herbert S.L., Euling S.Y. Use of comparative genomics approaches to characterize interspecies differences in response to environmental chemicals: challenges, opportunities, and research needs. Toxicol. Appl. Pharmacol. 2011.
2. Euling S.Y., White L.D., Kim A.S., Sen B., Wilson V.S., Keshava C., Keshava N., Hester S., Ovacik A.M., Ierapetritou M.G., Androulakis I.P., Gaido K.W. Use of genomic data in risk assessment case study: II. Evaluation of the dibutyl phthalate toxicogenomic data set. Toxicol. Appl. Pharmacol. 2011.
3. Shindo S., Numazawa S., Yoshida T. A physiological role of AMP-activated protein kinase in phenobarbital-mediated constitutive androstane receptor activation and CYP2B induction. Biochem. J. 2007, 401:735-741.
4. Waters M.D., Jackson M., Lea I. Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat. Res. 2010, 705:184-200.
5. Wilson V.S., Keshava N., Hester S., Segal D., Chiu W., Thompson C.M., Euling S.Y. Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. Toxicol. Appl. Pharmacol. 2011.
6. Ihlaseh S.M., Bailey K.A., Hester S.D., Jones C., Ren H., Cardoso A.P., Oliveira M.L., Wolf D.C., de Camargo J.L. Transcriptional profile of diuron-induced toxicity on the urinary bladder of male Wistar rats to inform mode of action. Toxicol. Sci. 2011, 122:330-338.
7. Zarn J.A., Bruschweiler B.J., Schlatter J.R. Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. Environ. Health Perspect. 2003, 111:255-261.
8. Vanden Bossche H., Marichal P., Gorrens J., Coene M.C., Willemsens G., Bellens D., Roels I., Moereels H., Janssen P.A. Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses 1989, 32(Suppl 1):35-52.
9. INCHEM, Monograph 768. Propiconazole Part II Toxicology. In: Pesticide residues in food: 1987 Evaluations, 1987, pp. 19.
10. Hasegawa R., Ito N. Liver medium-term bioassay in rats for screening of carcinogens and modifying factors in hepatocarcinogenesis. Food Chem. Toxicol. 1992, 30:979-992.
11. Klaunig J.E., Kamendulis L.M. The role of oxidative stress in carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 2004, 44:239-267.
12. Pitot H.C., Dragan Y.P., Teeguarden J., Hsia S., Campbell H. Quantitation of multistage carcinogenesis in rat liver. Toxicol. Pathol. 1996, 24:119-128.
13. Ronis M.J., Ingelman-Sundberg M., Badger T.M. Induction, suppression and inhibition of multiple hepatic cytochrome P450 isozymes in the male rat and bobwhite quail (Colinus virginianus) by ergosterol biosynthesis inhibiting fungicides (EBIFs). Biochem. Pharmacol. 1994, 48:1953-1965.
14. Ho B.E., Shen D.D., McCune J.S., Bui T., Risler L., Yang Z., Ho R.J. Effects of garlic on cytochromes P450 2C9- and 3A4-mediated drug metabolism in human hepatocytes. Sci. Pharm. 2010, 78:473-481.
15. Xu C., Li C.Y., Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28:249-268.
16. I. Dewhurst, V. Dellarco, International Programme on Chemical Safety Evaluations 2004, Part 2 Propiconazole. 2004, pp. 281-320. http://www.whqlibdoc.who.int/publications/2006/9241665203_eng.pdf.
17. Chen P.-J., Moore T., Nesnow S. Cytotoxic effects of propiconazole and its metabolites in mouse and human hepatoma cells and primary mouse hepatocytes. Toxicol. In Vitro 2008, 22:1476-1483.
18. Maglich J.M., Stoltz C.M., Goodwin B., Hawkins-Brown D., Moore J.T., Kliewer S.A. Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol. Pharmacol. 2002, 62:638-646.
19. Lemaire G., Mnif W., Pascussi J.M., Pillon A., Rabenoelina F., Fenet H., Gomez E., Casellas C., Nicolas J.C., Cavailles V., Duchesne M.J., Balaguer P. Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. Toxicol. Sci. 2006, 91:501-509.
20. Hafner M., Rezen T., Rozman D. Regulation of hepatic cytochromes p450 by lipids and cholesterol. Curr. Drug Metab. 2011, 12:173-185.
21. Johansson L., Rudling M., Scanlan T.S., Lundasen T., Webb P., Baxter J., Angelin B., Parini P. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc. Natl. Acad. Sci. USA 2005, 102:10297-10302.
22. del Castillo-Olivares A., Gil G. Role of FXR and FTF in bile acid-mediated suppression of cholesterol 7alpha-hydroxylase transcription. Nucleic Acids Res. 2000, 28:3587-3593.
23. Johnson E.F., Hsu M.H., Savas U., Griffin K.J. Regulation of P450 4A expression by peroxisome proliferator activated receptors. Toxicology 2002, 181-182:203-206.
24. Nesnow S., Ward W., Moore T., Ren H., Hester S.D. Discrimination of tumorigenic triazole conazoles from phenobarbital by transcriptional analyses of mouse liver gene expression. Toxicol. Sci. 2009, 110:68-83.
25. Leslie C., Reidy G.F., Stacey N.H. The effects of propiconazole on hepatic xenobiotic biotransformation in the rat. Biochem. Pharmacol. 1988, 37:4177-4181.
26. Sun G., Thai S.F., Tully D.B., Lambert G.R., Goetz A.K., Wolf D.C., Dix D.J., Nesnow S. Propiconazole-induced cytochrome P450 gene expression and enzymatic activities in rat and mouse liver. Toxicol. Lett. 2005, 155:277-287.
27. Chen P.J., Padgett W.T., Moore T., Winnik W., Lambert G.R., Thai S.F., Hester S.D., Nesnow S. Three conazoles increase hepatic microsomal retinoic acid metabolism and decrease mouse hepatic retinoic acid levels in vivo. Toxicol. Appl. Pharmacol. 2009, 234:143-155.
28. Allen J.W., Wolf D.C., George M.H., Hester S.D., Sun G., Thai S.F., Delker D.A., Moore T., Jones C., Nelson G., Roop B.C., Leavitt S., Winkfield E., Ward W.O., Nesnow S. Toxicity profiles in mice treated with hepatotumorigenic and non-hepatotumorigenic triazole conazole fungicides: propiconazole, triadimefon, and myclobutanil. Toxicol. Pathol. 2006, 34:853-862.
29. Ward W.O., Delker D.A., Hester S.D., Thai S.F., Wolf D.C., Allen J.W., Nesnow S. Transcriptional profiles in liver from mice treated with hepatotumorigenic and nonhepatotumorigenic triazole conazole fungicides: propiconazole, triadimefon, and myclobutanil. Toxicol. Pathol. 2006, 34:863-878.
30. Kotokorpi P., Gardmo C., Nystrom C.S., Mode A. Activation of the glucocorticoid receptor or liver X receptors interferes with growth hormone-induced akr1b7 gene expression in rat hepatocytes. Endocrinology 2004, 145:5704-5713.
31. Lefrancois-Martinez A.M., Tournaire C., Martinez A., Berger M., Daoudal S., Tritsch D., Veyssiere G., Jean C. Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells. J. Biol. Chem. 1999, 274:32875-32880.
32. Ortiz P.A., Bruno M.E., Moore T., Nesnow S., Winnik W., Ge Y. Proteomic analysis of propiconazole responses in mouse liver: comparison of genomic and proteomic profiles. J. Proteome Res. 2010, 9:1268-1278.
33. Nesnow S., Padgett W.T., Moore T. Propiconazole induces alterations in the hepatic metabolome of mice. relevance to propiconazole-induced hepatocarcinogenesis. Toxicol. Sci. 2011, 120:297-309.
34. Bruno M., Moore T., Nesnow S., Ge Y. Protein Carbonyl Formation in Response to Propiconazole-Induced Oxidative Stress. J. Proteome Res. 2009, 8:2070-2078.
35. Nesnow S., Grindstaff R.D., Lambert G., Padgett W.T., Bruno M., Ge Y., Chen P.J., Wood C.E., Murphy L. Propiconazole increases reactive oxygen species levels in mouse hepatic cells in culture and in mouse liver by a cytochrome P450 enzyme mediated process. Chem. Biol. Interact. 2011, 194:79-89.
36. Ingelman-Sundberg M., Hagbjork A.L. On the significance of the cytochrome P-450-dependent hydroxyl radical-mediated oxygenation mechanism. Xenobiotica 1982, 12:673-686.
37. Serron S.C., Dwivedi N., Backes W.L. Ethylbenzene induces microsomal oxygen free radical generation: antibody-directed characterization of the responsible cytochrome P450 enzymes. Toxicol. Appl. Pharmacol. 2000, 164:305-311.
38. Vuchetich P.J., Bagchi D., Bagchi M., Hassoun E.A., Tang L., Stohs S.J. Naphthalene-induced oxidative stress in rats and the protective effects of vitamin E succinate. Free Radic. Biol. Med. 1996, 21:577-590.
39. Green R.M., Hodges N.J., Chipman J.K., O'Donovan M.R., Graham M. Reactive oxygen species from the uncoupling of human cytochrome P450 1B1 may contribute to the carcinogenicity of dioxin-like polychlorinated biphenyls. Mutagenesis 2008, 23:457-463.
40. Schlezinger J.J., Struntz W.D., Goldstone J.V., Stegeman J.J. Uncoupling of cytochrome P450 1A and stimulation of reactive oxygen species production by co-planar polychlorinated biphenyl congeners. Aquat. Toxicol. 2006, 77:422-432.
41. Schlezinger J.J., White R.D., Stegeman J.J. Oxidative inactivation of cytochrome P-450 1A (CYP1A) stimulated by 3,3',4,4'-tetrachlorobiphenyl: production of reactive oxygen by vertebrate CYP1As. Mol. Pharmacol. 1999, 56:588-597.
42. Caro A.A., Cederbaum A.I. Oxidative stress, toxicology, and pharmacology of CYP2E1. Annu. Rev. Pharmacol. Toxicol. 2004, 44:27-42.
43. Ekstrom G., Ingelman-Sundberg M. Mechanisms of lipid peroxidation dependent upon cytochrome P-450 LM2. Eur. J. Biochem. 1986, 158:195-201.
44. Dostalek M., Brooks J.D., Hardy K.D., Milne G.L., Moore M.M., Sharma S., Morrow J.D., Guengerich F.P. In vivo oxidative damage in rats is associated with barbiturate response but not other cytochrome P450 inducers. Mol. Pharmacol. 2007, 72:1419-1424.
45. Dostalek M., Hardy K.D., Milne G.L., Morrow J.D., Chen C., Gonzalez F.J., Gu J., Ding X., Johnson D.A., Johnson J.A., Martin M.V., Guengerich F.P. Development of oxidative stress by cytochrome P450 induction in rodents is selective for barbiturates and related to loss of pyridine nucleotide-dependent protective systems. J. Biol. Chem. 2008, 283:17147-17157.
46. Strolin-Benedetti M., Brogin G., Bani M., Oesch F., Hengstler J.G. Association of cytochrome P450 induction with oxidative stress in vivo as evidenced by 3-hydroxylation of salicylate. Xenobiotica 1999, 29:1171-1180.
47. Sai Y., Dai R., Yang T.J., Krausz K.W., Gonzalez F.J., Gelboin H.V., Shou M. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 2000, 30:327-343.
48. Ishihara Y., Shiba D., Shimamoto N. Enhancement of DMNQ-induced hepatocyte toxicity by cytochrome P450 inhibition. Toxicol. Appl. Pharmacol. 2006, 214:109-117.
49. Imaoka S., Osada M., Minamiyama Y., Yukimura T., Toyokuni S., Takemura S., Hiroi T., Funae Y. Role of phenobarbital-inducible cytochrome P450s as a source of active oxygen species in DNA-oxidation. Cancer Lett. 2004, 203:117-125.
50. Marill J., Cresteil T., Lanotte M., Chabot G.G. Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol. Pharmacol. 2000, 58:1341-1348.
51. Marill J., Idres N., Capron C.C., Nguyen E., Chabot G.G. Retinoic acid metabolism and mechanism of action: a review. Curr. Drug Metab. 2003, 4:1-10.
52. Hester S., Moore T., Padgett W.T., Murphy L., Wood C.E., Nesnow S. The hepatocarcinogenic conazoles: cyproconazole, epoxiconazole, and propiconazole induce a common set of toxicological and transcriptional responses. Toxicol. Sci. 2012, 127:54-65.
53. Trosken E.R., Adamska M., Arand M., Zarn J.A., Patten C., Volkel W., Lutz W.K. Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles. Toxicology 2006, 228:24-32.
54. Ross J.A., Leavitt S.A., Schmid J.E., Nelson G.B. Quantitative changes in endogenous DNA adducts correlate with conazole in vivo mutagenicity and tumorigenicity. Mutagenesis 2012.
55. Ross J.A., Moore T., Leavitt S.A. In vivo mutagenicity of conazole fungicides correlates with tumorigenicity. Mutagenesis 2009, 24:149-152.
56. Ross J.A., Leavitt S.A. Analysis of the mutations induced by conazole fungicides in vivo. Mutagenesis 2010, 25:231-234.
57. Teixeira C., Pratt M.A. CDK2 is a target for retinoic acid-mediated growth inhibition in MCF-7 human breast cancer cells. Mol. Endocrinol. 1997, 11:1191-1202.
58. Liu C., Chung J., Seitz H.K., Russell R.M., Wang X.D. Chlormethiazole treatment prevents reduced hepatic vitamin A levels in ethanol-fed rats. Alcohol. Clin. Exp. Res. 2002, 26:1703-1709.
59. Wang X.D. Retinoids and alcohol-related carcinogenesis. J. Nutr. 2003, 133:287S-290S.
60. Chung J., Chavez P.R., Russell R.M., Wang X.D. Retinoic acid inhibits hepatic Jun N-terminal kinase-dependent signaling pathway in ethanol-fed rats. Oncogene 2002, 21:1539-1547.
61. L. Murphy, T. Moore, S. Nesnow, Reversible effect of all-trans-retinoic acid on AML12 hepatocyte proliferation and cell cycle progression [abstract], in: 101st Annual Meeting of the American Association of Cancer Research, Washington, DC, AACR, Philadelphia, PA, 2010, pp. 206 (Abstract nr 1076).
62. Brown M.S., Goldstein J.L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 1980, 21:505-517.
63. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
64. Duncan R.E., El-Sohemy A., Archer M.C. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity. J. Biol. Chem. 2004, 279:33079-33084.
65. Pruitt K., Der C.J. Ras and Rho regulation of the cell cycle and oncogenesis. Cancer Lett. 2001, 171:1-10.
66. Murphy L.A., Moore T., Nesnow S. Propiconazole-enhanced hepatic cell proliferation is associated with dysregulation of the cholesterol biosynthesis pathway leading to activation of Erk1/2 through Ras farnesylation. Toxicol. Appl. Pharmacol. 2012, 260:146-154.
67. Mateyak M.K., Obaya A.J., Sedivy J.M. C-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol. Cell. Biol. 1999, 19:4672-4683.
68. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics. CA Cancer J. Clin. 2002, 55(2005):74-108.
69. Peychal S.E., Bilger A., Pitot H.C., Drinkwater N.R. Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6 Mb on chromosome 17. Carcinogenesis 2009, 30:879-885.
70. Wolf D.C., Allen J.W., George M.H., Hester S.D., Sun G., Moore T., Thai S.F., Delker D., Winkfield E., Leavitt S., Nelson G., Roop B.C., Jones C., Thibodeaux J., Nesnow S. Toxicity profiles in rats treated with tumorigenic and nontumorigenic triazole conazole fungicides: propiconazole, triadimefon, and myclobutanil. Toxicol. Pathol. 2006, 34:895-902.
71. Akiyama T.E., Gonzalez F.J. Regulation of P450 genes by liver-enriched transcription factors and nuclear receptors. Biochim. Biophys. Acta 2003, 1619:223-234.
72. Guengerich F.P. Human cytochrome P450 enzymes. Cytochrome P450: Structure, Mechanisms, and Biochemistry 1995, 473-575. Plenum, New York. P.R. Ortiz de Montellano (Ed.).
73. Faucette S.R., Wang H., Hamilton G.A., Jolley S.L., Gilbert D., Lindley C., Yan B., Negishi M., LeCluyse E.L. Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers. Drug Metab. Dispos. 2004, 32:348-358.
74. Zangar R.C., Bollinger N., Weber T.J., Tan R.M., Markillie L.M., Karin N.J. Reactive oxygen species alter autocrine and paracrine signaling. Free Radic. Biol. Med. 2011, 51:2041-2047.
75. Wang T., Ma X., Krausz K.W., Idle J.R., Gonzalez F.J. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J. Pharmacol. Exp. Ther. 2008, 324:674-684.
76. Muindi J., Frankel S.R., Miller W.H., Jakubowski A., Scheinberg D.A., Young C.W., Dmitrovsky E., Warrell R.P. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 1992, 79:299-303.
77. Muindi J.R., Frankel S.R., Huselton C., DeGrazia F., Garland W.A., Young C.W., Warrell R.P. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992, 52:2138-2142.
78. Osmak M. Statins and cancer: current and future prospects. Cancer Lett. 2012, 324:1-12.
79. Relja B., Meder F., Wilhelm K., Henrich D., Marzi I., Lehnert M. Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int. J. Mol. Med. 2010, 26:735-741.
80. Ross J.A., Leavitt S.A. Response to commentary: "Re-evaluation of the Big Blue(R) mouse assay of propiconazole suggests lack of mutagenicity" Environ. Mol. Mutagen. 2012, 53:574-577.
81. Shane B.S., Zeiger E., Piegorsch W.W., Booth E.D., Goodman J.I., Peffer R.C. Re-evaluation of the Big Blue(R) mouse assay of propiconazole suggests lack of mutagenicity. Environ. Mol. Mutagen. 2012, 53:1-9.